What damage might Monday's ongoing selloff do to the technical set-up for stocks? Well, in a note published on Sunday, BTIG chartist guru Jonathan Krinsky observed that Friday's action had already sug ...

Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

BTIG analyst Vincent Caintic updated the firm's stance on American Express (NYSE:AXP) shares, raising the price target to ...

Papa Johns’ blueprint under CEO Todd Penegor has several targets, from core strength focus to data leverage to tech stack ...

CAD to Participate in the BTIG at Snowbird:12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceNASHUA, N.H., Jan.

In a report released today, Eric Hagen from BTIG maintained a Buy rating on Dynex Capital (DX – Research Report), with a price target of ...

In terms of valuation, Akebia Therapeutics Inc’s market capitalization stands at $519.27 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

SoFi (SOFI) surpassed analyst expectations in fourth quarter revenue and adjusted earnings per share (EPS), but its stock is ...

CAD to Participate in the BTIG at Snowbird:12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference NASHUA, N.H., Jan. 27, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ...

Tuesday, shares of Ideaya Biosciences (NASDAQ:IDYA), trading at $22.18 near its 52-week low of $22.10, drew attention as BTIG analysts maintained their Buy rating and $62.00 price target.

BTIG lowered the firm’s price target on D.R. Horton (DHI) to $171 from $186 and keeps a Buy rating on the shares. The company’s Q1 earnings topped consensus estimates with stronger deliveries ...

BTIG lowered the firm’s price target on Evolent Health (EVH) to $20 from $29 but keeps a Buy rating on the shares. The firm notes it was disappointed by the company’s comments around higher ...